Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s – CNBC
Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s CNBCNovo Nordisk (NVO) Sets Pipeline Sales Target Above $23 Billion By 2035 Yahoo FinanceWegovy maker Novo shares slump as management grilled on pricing, M&A ReutersNovo’s CEO knows the drugmaker needs to build confidence Endpoints NewsNovo Nordisk: Capital Markets Day Reveals Its Next Growth Engine (NYSE:NVO) Seeking Alpha
সূত্র: মূল সংবাদসূত্র
